Envestnet Asset Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $20.3M | Buy |
89,424
+6,125
| +7% | +$1.09M | ﹤0.01% | 1439 |
|
|
2026
Q1 | $14.4M | Buy |
83,299
+13,169
| +19% | +$2.44M | ﹤0.01% | 1576 |
|
|
2025
Q4 | $14M | Sell |
70,130
-11,463
| -14% | -$2.08M | ﹤0.01% | 1466 |
|
|
2025
Q3 | $12.8M | Sell |
81,593
-3,928
| -5% | -$624K | ﹤0.01% | 1598 |
|
|
2025
Q2 | $13M | Sell |
85,521
-135,740
| -61% | -$18.1M | ﹤0.01% | 1560 |
|
|
2025
Q1 | $33.3M | Sell |
221,261
-22,973
| -9% | -$3.85M | 0.01% | 897 |
|
|
2024
Q4 | $45.1M | Sell |
244,234
-41,369
| -14% | -$7.97M | 0.01% | 767 |
|
|
2024
Q3 | $56.3M | Sell |
285,603
-33,574
| -11% | -$6.98M | 0.02% | 662 |
|
|
2024
Q2 | $65.9M | Buy |
319,177
+11,514
| +4% | +$2.61M | 0.02% | 568 |
|
|
2024
Q1 | $83.4M | Buy |
307,663
+39,097
| +15% | +$9.34M | 0.03% | 490 |
|
|
2023
Q4 | $63.5M | Sell |
268,566
-250
| -0.1% | -$49.2K | 0.03% | 522 |
|
|
2023
Q3 | $52.7M | Buy |
268,816
+88,862
| +49% | +$18.2M | 0.02% | 559 |
|
|
2023
Q2 | $37.8M | Buy |
179,954
+13,741
| +8% | +$2.73M | 0.02% | 613 |
|
|
2023
Q1 | $33.5M | Buy |
166,213
+5,850
| +4% | +$1.33M | 0.02% | 637 |
|
|
2022
Q4 | $34.9M | Sell |
160,363
-3,456
| -2% | -$755K | 0.02% | 590 |
|
|
2022
Q3 | $32.2M | Buy |
163,819
+6,220
| +4% | +$1.34M | 0.02% | 570 |
|
|
2022
Q2 | $33.7M | Sell |
157,599
-3,805
| -2% | -$930K | 0.02% | 558 |
|
|
2022
Q1 | $45.8M | Buy |
161,404
+20,665
| +15% | +$6.37M | 0.02% | 511 |
|
|
2021
Q4 | $53M | Buy |
140,739
+12,972
| +10% | +$5.04M | 0.03% | 475 |
|
|
2021
Q3 | $52.7M | Buy |
127,767
+9,226
| +8% | +$3.83M | 0.03% | 443 |
|
|
2021
Q2 | $43.9M | Sell |
118,541
-17,659
| -13% | -$5.9M | 0.02% | 487 |
|
|
2021
Q1 | $39.5M | Buy |
136,200
+15,632
| +13% | +$4.35M | 0.03% | 472 |
|
|
2020
Q4 | $30.1M | Buy |
120,568
+6,597
| +6% | +$1.57M | 0.02% | 494 |
|
|
2020
Q3 | $25.8M | Buy |
113,971
+4,795
| +4% | +$995K | 0.02% | 471 |
|
|
2020
Q2 | $19M | Buy |
109,176
+3,121
| +3% | +$498K | 0.02% | 541 |
|
|
2020
Q1 | $13.4M | Buy |
106,055
+35,003
| +49% | +$5.25M | 0.02% | 570 |
|
|
2019
Q4 | $10.9M | Buy |
71,052
+313
| +0.4% | +$43.3K | 0.01% | 774 |
|
|
2019
Q3 | $9.36M | Buy |
70,739
+1,196
| +2% | +$160K | 0.01% | 777 |
|
|
2019
Q2 | $9.87M | Buy |
69,543
+11,932
| +21% | +$1.62M | 0.01% | 735 |
|
|
2019
Q1 | $8.37M | Buy |
57,611
+5,388
| +10% | +$708K | 0.01% | 764 |
|
|
2018
Q4 | $5.91M | Buy |
52,223
+45,188
| +642% | +$5.66M | 0.01% | 807 |
|
|
2018
Q3 | $946K | Sell |
7,035
-2,942
| -29% | -$363K | ﹤0.01% | 752 |
|
|
2018
Q2 | $1.12M | Buy |
9,977
+7,912
| +383% | +$855K | ﹤0.01% | 1014 |
|
|
2018
Q1 | $220K | Sell |
2,065
-11,664
| -85% | -$1.26M | ﹤0.01% | 1545 |
|
|
2017
Q4 | $1.5M | Sell |
13,729
-157
| -1% | -$17.1K | ﹤0.01% | 1054 |
|
|
2017
Q3 | $1.5M | Buy |
13,886
+12,497
| +900% | +$1.28M | ﹤0.01% | 1016 |
|
|
2017
Q2 | $142K | Sell |
1,389
-367
| -21% | -$33.8K | ﹤0.01% | 2000 |
|
|
2017
Q1 | $156K | Sell |
1,756
-29
| -2% | -$2.46K | ﹤0.01% | 2015 |
|
|
2016
Q4 | $135K | Buy |
1,785
+526
| +42% | +$39.9K | ﹤0.01% | 2058 |
|
|
2016
Q3 | $105K | Sell |
1,259
-979
| -44% | -$82.1K | ﹤0.01% | 2284 |
|
|
2016
Q2 | $185K | Sell |
2,238
-458
| -17% | -$37.7K | ﹤0.01% | 2140 |
|
|
2016
Q1 | $205K | Sell |
2,696
-23
| -0.8% | -$1.7K | ﹤0.01% | 2051 |
|
|
2015
Q4 | $219K | Buy |
2,719
+160
| +6% | +$11.5K | ﹤0.01% | 1984 |
|
|
2015
Q3 | $163K | Buy |
+2,559
| New | +$184K | ﹤0.01% | 2118 |
|
|
2015
Q1 | – | Sell |
-291
| Closed | -$19K | – | 2095 |
|
|
2014
Q4 | $19K | Sell |
291
-21
| -7% | -$1.32K | ﹤0.01% | 1764 |
|
|
2014
Q3 | $19K | Buy |
312
+76
| +32% | +$4.35K | ﹤0.01% | 1898 |
|
|
2014
Q2 | $13K | Buy |
236
+142
| +151% | +$7.79K | ﹤0.01% | 1914 |
|
|
2014
Q1 | $6K | Sell |
94
-53
| -36% | -$3.09K | ﹤0.01% | 2040 |
|
|
2013
Q4 | $8K | Sell |
147
-38
| -21% | -$1.91K | ﹤0.01% | 1825 |
|
|
2013
Q3 | $9K | Sell |
185
-83
| -31% | -$3.81K | ﹤0.01% | 1735 |
|
|
2013
Q2 | $11K | Buy |
+268
| New | +$11.5K | ﹤0.01% | 1621 |
|
Other funds holding CRL
AI
Envestnet Asset Management's CRL Position: Q2 2026 in Review
Envestnet Asset Management increased its Charles River Laboratories (CRL) stake by 7.4% in Q2 2026, buying an estimated $1.09M and bringing the position to 89,424 shares worth $20.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1439.
Envestnet Asset Management first reported a position in CRL in Q2 2013 and has held it in 51 quarters since. The position peaked at $83.4M in Q1 2024. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Envestnet Asset Management held 89,424 shares of Charles River Laboratories worth $20.3M as of Q2 2026.
- Envestnet Asset Management bought 6,125 Charles River Laboratories shares in Q2 2026, an estimated $1.09M.
- Charles River Laboratories made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #1439 holding.
- Envestnet Asset Management first reported a position in Charles River Laboratories in Q2 2013 and has held it in 51 quarters since.
- Envestnet Asset Management's Charles River Laboratories position peaked at $83.4M in Q1 2024.
- 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.